CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Health Inc., a biotechnology company pioneering transformative medicines for patients with conditions where disrupted amino acid biology plays a critical role, announced today that Robert Connelly, President and Chief Executive Officer, will present a company overview at the Jefferies 2016 Healthcare Conference in New York, N.Y. The presentation will take place June 9, 2016, at 9 a.m. EDT.
About Axcella Health
Axcella Health is pioneering
revolutionary new medicines with a focus on amino acid homeostasis. The
company has discovered more than 2,000 diseases with amino acid
imbalances and developed a systems pharmacology approach to restore
health at the cellular level. Axcella’s proprietary platform is
clinically validated across several indication areas, with
clinical-stage candidates in muscle, neurodegenerative and liver
conditions. Axcella is led by a team with a strong track record of
leaving a lasting impact on the therapeutic landscape through the
development of novel products. The company was founded by VentureLabs,
the Innovation Foundry at Flagship Ventures, and has received additional
funding from Fidelity Research & Management Group, Gurnet Point Capital
and Nestlé Health Science. Axcella is based in Cambridge, Mass. For more
information, visit www.axcellahealth.com.
Contacts
Media Contact
Ten Bridge Communications
Dan Quinn,
781-475-7974
dan@tenbridgecommunications.com
or
Company
Contact
Axcella Health
Christine Lafontant, 857-320-2250
clafontant@axcellahealth.com